Skip to main content
In stock | Targeted Therapy (Investigational)

Gartisertib

Oncology Type Solid Tumour
Drug Class / Mechanism DNA Damage Response Inhibitor
No Image
Description

Gartisertib is classified as a DNA Damage Response Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Investigational)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3